DeepMed Research

Hunan Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.hnca.org.cn

Clinical Trials

A Study of Carilizumab Combined With Concurrent Chemoradiotherapy

Phase 2

Conditions: Cervical Cancer

Interventions: Drug: Camrelizumab
Drug: Cisplatin or Carboplatin

First Posted Date: 2021-12-09

Last Posted Date: 2021-12-09

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 46

Registration Number: NCT05151549

Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer

Completed

Conditions: Metastatic Breast Cancer
Gene Abnormality
Circulating Tumor DNA

Interventions: Diagnostic Test: ctDNA testing

First Posted Date: 2021-10-15

Last Posted Date: 2022-06-22

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 223

Registration Number: NCT05079074

Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer

Phase 2

Conditions: Small Cell Lung Cancer

Interventions: Drug: Anlotinib Plus Penpulimab

First Posted Date: 2021-08-12

Last Posted Date: 2021-08-12

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 73

Registration Number: NCT05001971

Locations: 🇨🇳
Nong Yang, Changsha, Hunan, China

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

Phase 2

Conditions: Cervical Cancer

Interventions: Drug: Camrelizumab
Drug: Cisplatin or Carboplatin

First Posted Date: 2021-07-23

Last Posted Date: 2021-08-10

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 46

Registration Number: NCT04974827

Locations: 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Conditions: Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Drug: PD-1 inhibitor
Drug: Albumin Paclitaxel
Drug: Cisplatin

First Posted Date: 2021-06-10

Last Posted Date: 2021-06-10

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 53

Registration Number: NCT04922450

Locations: 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China

Research on Optimization and Evaluation of Oral Cancer Screening Methods

Early Phase 1

Conditions: Oral Cancer

Interventions: Other: clinical observation combined with pathological biopsy

First Posted Date: 2021-06-09

Last Posted Date: 2021-06-09

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 10000

Registration Number: NCT04919460

A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

Phase 2

Conditions: Hepatocellular Carcinoma
Immune Checkpoint Inhibitors

Interventions: Drug: Camrelizumab combined Apatinib regimen

First Posted Date: 2021-04-01

Last Posted Date: 2021-04-01

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT04826406

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Camrelizumab, Albumin Paclitaxel, Carboplatin

First Posted Date: 2021-02-23

Last Posted Date: 2021-02-23

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 28

Registration Number: NCT04767295

Locations: 🇨🇳
Wenxiang Wang, Changsha, Hunan, China

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Phase 2

Active, not recruiting

Conditions: Adenocarcinoma of the Lung

Interventions: Drug: Camrelizumab
Drug: Albumin Paclitacxel
Drug: Apatinib

First Posted Date: 2020-07-07

Last Posted Date: 2022-12-02

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 63

Registration Number: NCT04459078

Locations: 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
🇨🇳
The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Phase 2

Recruiting

Conditions: Immune Checkpoint Inhibitor
Epigenetic Disorder
Chemotherapy Effect
NK/T-cell Lymphoma of Nasal Cavity

Interventions: Drug: Anti-PD-1 antibody+Peg-Asparaginase+Chidamide

First Posted Date: 2020-06-04

Last Posted Date: 2020-07-07

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 35

Registration Number: NCT04414969

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy